Advertisement

Topics

Probiodrug AG Company Profile

21:37 EST 12th December 2018 | BioPortfolio

Probiodrug AG was established in 1997 as a spin off of the "Hans-Knöll-Institut für Wirkstoffforschung". Probiodrug is a wholly privately owned science driven drug development company, founded by Dr.'s. Hans-Ulrich Demuth and Konrad Glund, biochemists by education. The company is financed through venture capital and silent partnerships and successfully acquired R&D grants. The scientific advisory board is composed of international experts in fields relevant to the company's core business. Probiodrug's core competence is drug development based on target evaluation. Targets are serine and cysteine proteases, among them dipeptidyl peptidases I, IV and prolyl endopeptidase. DP IV is an ubiquitous enzyme which plays a key role in gastrointestinal peptide hormone regulation and in immune response (CD26) providing new therapeutic targets for metabolic disorders including diabetes and obesity as well immune diseases. Modulation of prolyl endopeptidase is a target for treatment of neuronal disorders as dementia. Based on the knowledge of pathophysiological mechanisms, specific and selective inhibitors of regulatory proteases have been identified as lead compounds for a target-orientated, rational drug design. probiodrug´s task is to develop new potential drug candidates from the in vitro characterization through preclinical studies up to a clinical proof of concept in man as an appropriate stage for licensing to the pharmaceutical industry.

Location

Weinbergweg 22
Halle/Saale
D-06120
Germany

Contact

Phone: 49-345-5559900
Fax: 49-345-5559901
Email: info@probiodrug.de


News Articles [22 Associated News Articles listed on BioPortfolio]

Probiodrug: Ergebnisse im Rahmen der Erwartungen

Von Probiodrug kommt am Donnerstag ein Business-Update zum Verlauf der Aktivitäten im dritten Quartal. Unter dem Strich hat sich der Verlust des Biotechunternehmens kaum verändert. Probiodrug bezif....

Probiodrug (PBD-NA): Positive read-across from -2-

DJ Probiodrug (PBD-NA): Positive read-across from BAN2401 Phase II data Dow Jones received a payment from EQS/DGAP to publish this press release. goetzpartners securities Limited Probiodrug (PBD-N...

Press Release: Probiodrug AG: Loss announcement according to --92 paragraph 1 of the German Stock Corporation Act

Probiodrug / Probiodrug AG: Loss announcement according to --92 paragraph 1 of the German Stock Corporation Act . Processed and transmitted by West Corporation. The issuer is solely responsible fo...

Probiodrug (PBD) - Support for Abeta theory from Biogen/Eisai

Edison Investment Research - Pharmaceutical & healthcare - Probiodrug: We believe one of the main reasons for the devaluation of Probiodrug’s shares over the past year was the largely disappoint...

ProBiodrug Aktie: Was ist hier los?

Nach einer alles andere als guten Performance in diesem Jahr kann die ProBiodrug Aktie seit dem Start der neuen Woche deutlich an Terrain gewinnen. Unter hohen Umsätzen schießt der Aktienkurs des U....

DGAP-News: Probiodrug veröffentlicht Quartalsbericht für das dritte Quartal 2018 (deutsch)

Probiodrug veröffentlicht Quartalsbericht für das dritte Quartal 2018 DGAP-News: Probiodrug AG / Schlagwort(e): Quartalsergebnis Probiodrug veröffentlicht Quartalsbericht für das dritte Quartal 20...

Probiodrug: Ergebnisse "sind sehr ermutigend"

Probiodrug hat am Dienstag Neuigkeiten zum Alzheimer-Medikamentenprojekt PQ912 vorgelegt. In einem Alzheimer-Magazin seien Daten zur Saphir-Studie vorgelegt worden, heißt es. "Die Ergebnisse der SA.....

DGAP-AFR: Probiodrug AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG

Dow Jones hat von EQS/DGAP eine Zahlung für die Verbreitung dieser Pressemitteilung über sein Netzwerk erhalten. DGAP Vorabbekanntmachung Finanzberichte: Probiodrug AG / Vorabbekanntmachung über di...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Probiodrug AG

Probiodrug AG was established in 1997 as a spin off of the "Hans-Knöll-Institut für Wirkstoffforschung". Probiodrug is a wholly privately owned science driven drug development company, founded by Dr...

More Information about "Probiodrug AG" on BioPortfolio

We have published hundreds of Probiodrug AG news stories on BioPortfolio along with dozens of Probiodrug AG Clinical Trials and PubMed Articles about Probiodrug AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Probiodrug AG Companies in our database. You can also find out about relevant Probiodrug AG Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record